Condition (MeSH)
Apnea
ClinicalTrials.gov lists 3,112 trials for Apnea or a narrower condition beneath it. ResMed has the most among industry and government lead sponsors, with 69.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
258 of the 3,112 trials are tagged with Apnea itself; the rest are tagged with a narrower condition beneath it.
When did Apnea trials start? (34)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 195
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 150 |
| 2025 | 168 |
| 2024 | 170 |
| 2023 | 154 |
| 2022 | 159 |
| 2021 | 159 |
| 2020 | 149 |
| 2019 | 195 |
| 2018 | 162 |
| 2017 | 175 |
Showing 10 of 34 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 170 trials starting in 2026 and about 170 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 220 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 1,925 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Apnea trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 64 |
| Phase 1/2 | 39 |
| Phase 2 | 113 |
| Phase 2/3 | 29 |
| Phase 3 | 115 |
| Phase 4 | 159 |
| Not applicable | 1,591 |
| Observational | 998 |
| Expanded access | 1 |
| Unknown | 3 |
How many Apnea trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 132 |
| Recruiting | 327 |
| Enrolling by invitation | 35 |
| Active, not recruiting | 70 |
| Available | 1 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Apnea trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| ResMed | 69 |
| Fisher and Paykel Healthcare | 68 |
| VA Office of Research and Development | 44 |
Which drugs are being tested for Apnea? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DEXMEDETOMIDINE | 11 |
| Trazodone | 9 |
| PROPOFOL | 9 |
| Solriamfetol | 8 |
| Armodafinil | 7 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Acetazolamide Pill | 24 |
| citrate of caffeine | 17 |
| Medicinal gas - oxygen (Nippon Gases 200 bar) | 12 |
| Eszopiclone 3 mg QHS | 11 |
| Drug-Induced Sleep Endoscopy (Propofol) | 10 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Apnea trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Second secondary endpoint | 947 | 1 |
| Hospitalization for any cause | 900 | 1 |
| Primary end point | 695 | 1 |
| Firt secondary endpoint | 662 | 1 |
| Unplanned hospitalization for worsening heart failure | 559 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Apnea? (330)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Lung Volume Change Under Apnoeic Oxygenation With Different Flow Rates in Children: A Single-Centre Prospective Randomized Controlled Non-Inferiority Trial. | Paediatric anaesthesia | 2026 | Yes |
| Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) use in a pediatric population: A prospective, randomized controlled trial. | Journal of clinical anesthesia | 2026 | Yes |
| Heart Rate Variability Does Not Predict Recurrence of Apnoea of Prematurity After Ceasing Caffeine Therapy: A Prospective Cohort Study. | Acta paediatrica (Oslo, Norway : 1992) | 2025 | Yes |
| Maturational delay in the brainstem auditory pathway of very preterm babies with apnoea. | Early human development | 2025 | Yes |
| Apnea After 2-Month Vaccinations in Hospitalized Preterm Infants: A Randomized Clinical Trial. | JAMA pediatrics | 2025 | Yes |
Showing 5 of 330 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.